CJC-1295 vs ipamorelin: different receptors, same axis
They are not alternatives. CJC-1295 is a GHRH analogue acting at the growth-hormone-releasing-hormone receptor; ipamorelin is a selective agonist at the ghrelin receptor. Because the receptors are distinct, most designs run them together and use each alone as the control.
| CJC-1295 (no DAC) | Ipamorelin | |
|---|---|---|
| Receptor | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Class | GHRH analogue | Secretagogue |
| Length | 29 residues | 5 residues |
| Molecular weight | See product page | 711.9 g/mol |
| Selectivity | GHRH-specific | No cortisol or prolactin release |
| Sold as | Single vial and blends | Single vial and blends |
Why are they paired rather than compared?
Two receptors on one axis means a combination can show whether the effects are additive or independent. Running either alone answers a narrower question, which is why both single vials and co-lyophilized blends are listed.
What makes ipamorelin selective?
Earlier secretagogues released cortisol and prolactin alongside growth hormone, which confounds any downstream measurement. Ipamorelin acts at the ghrelin receptor without those effects, so the readout stays attributable.
Does the DAC version change the comparison?
Substantially. With the drug affinity complex the GHRH analogue binds albumin and persists for days rather than minutes, turning a pulse into a plateau. The blends in this catalogue use the no-DAC form.
Common questions
Is CJC-1295 the same as modified GRF (1-29)?
The no-DAC form is, yes — both names describe the GHRH (1-29) backbone with four substitutions that resist degradation.
Can I buy them as one vial?
Yes. The CJC-1295 and ipamorelin blend is co-lyophilized at a fixed ratio. Buy the singles if the ratio is a variable in your design.
Where to go next
For laboratory research use only. Clinical trial results are cited as context and do not describe use of the material sold here.
